Breast Neoplasm Clinical Trial
Official title:
A Prospective, Single-Arm, Multi-Site, Clinical Evaluation of the SAVI SCOUT® Surgical Guidance System for the Location of Non-Palpable Breast Lesions During Excision
Verified date | February 2015 |
Source | Cianna Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to evaluate the performance of the SAVI SCOUT® Surgical
Guidance System (SAVI SCOUT). The SAVI SCOUT is a medical device, used to provide real-time
guidance during localized excisional biopsy or lumpectomy procedures, by helping the surgeon
locate and remove the desired tissue (i.e., the lesion and surrounding normal tissue). The
SAVI SCOUT has been 510K cleared.
The SAVI SCOUT is intended to assist surgeons in the location and retrieval of a
non-palpable abnormality as localized by radiographic or ultrasound methods. In this study,
the ability of the SAVI SCOUT to guide surgeons to find a lesion will be evaluated instead
of the standard technique of wire localization.
Status | Enrolling by invitation |
Enrollment | 150 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - • Patient has a non-palpable breast lesion that requires excision - Lesion depth = 3 cm from the skin surface in the supine position - Patient is scheduled for excision or BCT at a participating institution - Patient is between the ages of 18 and 90 years - Patient is female - Patient is willing and able to comply with all study procedures and be available to follow-up for the duration of the study - For lesions requiring multiple reflectors for localization, they must allow for reflectors to be placed = 1cm from one another relative to the coronal plane Subject Exclusion Criteria An individual who meets any of the following criteria will be excluded from participation in this study: - Patient had a previous ipsilateral breast cancer - Patient has multicentric breast cancer - Patient has Stage IV breast cancer - Patient has been treated with neoadjuvant chemotherapy - Patient is pregnant or lactating Exclusion Criteria: |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cianna Medical, Inc. | University of South Florida |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Success rate of reflector placement | How often the reflector can be successfully placed | intraoperative | No |
Secondary | Amount of tissue excised | Pathologic assessment of how much tissue was removed | Will be assessed by pathologist during standard pathology assessment which occurs 24-48 hours after surgery | No |
Secondary | Percent of cases with clear margins • Percent of cases requiring a second operation | How often patients are not required to have repeat procedures | Upon completion of pathologic assessment-which will occur within 24-48 hours after surgery | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03273426 -
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
|
N/A | |
Recruiting |
NCT04583124 -
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02913573 -
Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction
|
Phase 2 | |
Completed |
NCT03124095 -
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
|
N/A | |
Terminated |
NCT00251095 -
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT05576545 -
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
|
N/A | |
Active, not recruiting |
NCT03625635 -
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
|
N/A | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Withdrawn |
NCT03266562 -
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
|
N/A | |
Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06255808 -
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
|
||
Completed |
NCT04640220 -
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors
|
N/A | |
Completed |
NCT02970682 -
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02316561 -
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer
|
N/A | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06056414 -
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation
|
N/A | |
Recruiting |
NCT05427071 -
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT03740893 -
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
|
Phase 2 |